Reviva Pharmaceuticals (RVPH)
(Delayed Data from NSDQ)
$1.37 USD
0.00 (0.00%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.36 -0.01 (-0.73%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RVPH 1.37 0.00(0.00%)
Will RVPH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for RVPH based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for RVPH
Reviva Pharmaceuticals looks to raise $3M through direct offering; shares fall
Maxim Group Remains a Buy on Reviva Pharmaceuticals Holdings (RVPH)
Reviva Pharmaceuticals Progresses with Global Schizophrenia Trial
Reviva announces enrollment update for OLE study on brilaroxazine
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024